

Table 4 Preoperative patient characteristics of very high-risk cohort

	VHR unmatched cohort			Propensity score-matched cohort		
	LN yield≥15 (<i>n</i> =66)	LN yield<15 (<i>n</i> =59)	<i>p</i>	LN yield≥15 (<i>n</i> =35)	LN yield<15 (<i>n</i> =35)	<i>p</i>
Mean age, years (SD)	68.8 (5.6)	66.4 (6.6)	0.028	67.1 (5.9)	68.6 (5.4)	0.256
Mean BMI, kg/m ² (SD)	25.2 (3.0)	25.0 (3.2)	0.745	26.0 (3.3)	25.2 (3.6)	0.368
Mean PSA, ng/mL (SD)	16.2 (11.8)	20.7 (16.9)	0.085	19.2 (11.9)	19.5 (15.2)	0.930
Mean PV, mL (SD)	39.8 (13.1)	40.7 (23.7)	0.797	38.1 (14.6)	44.7 (28.9)	0.237
Clinical T-stage, <i>n</i> (%)			0.332			0.826
T1c	3 (4.5)	4 (6.8)		3 (8.6)	4 (11.4)	
T2a-c	26 (39.4)	17 (28.8)		13 (37.4)	10 (28.6)	
T3a-b	36 (54.5)	34 (57.6)		18 (51.4)	19 (54.3)	
T4	1 (1.5)	4 (6.8)		1 (2.9)	2 (5.7)	
Mean biopsy cores (SD)	15.5 (2.3)	17.0 (3.2)	0.002	16.1 (2.5)	15.7 (2.9)	0.564
Mean positive cores (SD)	7.4 (3.8)	6.5 (3.9)	0.231	7.7 (4.3)	7.1 (4.3)	0.526
ISUP grade group, <i>n</i> (%)			0.247			0.552
1-2	2 (3.0)	4 (6.8)		2 (5.7)	2 (5.7)	
3	2 (3.0)	5 (8.5)		2 (5.7)	2 (5.7)	
4	37 (56.1)	27 (45.8)		21 (60.0)	16 (45.7)	
5	25 (37.9)	23 (39.0)		10 (28.6)	15 (42.9)	
Androgen deprivation, <i>n</i> (%)			0.088			0.469
Received	17 (25.8)	24 (39.7)		17 (48.6)	13 (37.1)	
Not received	49 (74.2)	35 (60.3)		18 (51.4)	22 (62.9)	
Mean Briganti LNI, % (SD)	39.0 (21.2)	40.8 (22.7)	0.647	38.8 (19.8)	43.3 (24.5)	0.402

VHR=very high-risk (Johns Hopkins University criteria); LN=lymph node; SD=standard deviation; BMI=body mass index;

PSA=prostate-specific antigen; PV=prostate volume; ISUP=International Society of Urological Pathology